Advanced therapies in Belgium: read the white paper

24 October 2024

Following our successful Advanced Therapies event in October, Deloitte – with input from MEDVIA and BioWin – has produced a white paper on advanced therapeutic medicinal products (ATMPs) in Belgium. This paper is a reflection on the field and the challenges and opportunities of these therapies for the Belgian ecosystem.

Rapid scientific advancements are expanding the use of advanced therapies beyond rare diseases, making them more accessible and affordable in clinical practice. However, scaling these innovations requires a mature and well-funded ecosystem that supports the entire value chain – from innovation in manufacturing and logistics to talent development.

Belgium has the strategic location, specialized infrastructure, academic excellence and innovative healthcare system to become Europe’s biomanufacturing gateway!

Read the white paper here

Share this article

More news on this topic

call 2025.1 open thumb
MEDVIA news
19 February 2025

Better together

and are joining forces in a brand new organization

The members of MEDVIA and flanders.bio have voted to merge their activities in the first half of 2025. With a united voice, we will champion the entire healthtech and biotech ecosystem on the regional, federal and European stage.

The merger allows MEDVIA and flanders.bio to align activities and deliver more powerful support for our collective members. We will achieve greater impact with more dynamic networking opportunities, better directed funding and increased efficiency, sharpening our focus in common areas and drafting strategic roadmaps for Flanders.